Outlook Therapeutics (OTLK) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Voyager Therapeutics (VYGR) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 47.8% versus a loss of 55.2%. Over five years, VYGR leads with a -39.8% price change compared with -98.7% for OTLK. Voyager Therapeutics is the larger company by market cap ($146.0 million vs $137.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OTLK | VYGR |
|---|---|---|
| Share price | $0.564 | $2.37 |
| Market cap | $137.30M | $146.03M |
| 1-day change | -4.41% | -4.05% |
| YTD return | -64.30% | -37.15% |
| 1-year return | -55.24% | -47.78% |
| 5-year return | -98.66% | -39.76% |
| EPS (TTM) | $-0.70 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.54 | $5.55 |
| 52-week low | $0.161 | $2.33 |
| Distance from 52-week high | -77.78% | -57.30% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +791.84% | +528.27% |
| Average volume | 13.43M | 566.47K |
| Shares outstanding | 243.45M | 61.62M |
| Employees | 17 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
OTLK vs VYGR FAQ
Which is bigger, Outlook Therapeutics or Voyager Therapeutics?
Voyager Therapeutics (VYGR) is larger, with a market capitalization of $146.03M compared with $137.30M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, OTLK or VYGR?
VYGR returned -47.78% over the past 12 months, compared with -55.24% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Outlook Therapeutics and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.